NIH Grants Exclusive License for Autoimmune CAR Therapy
Published Date: 2/13/2026
Notice
Summary
The National Cancer Institute plans to give Kyverna Therapeutics an exclusive license to use a special CAR therapy that helps treat or prevent autoimmune diseases caused by B cells. This means Kyverna will be the only company allowed to develop and sell this innovative treatment. If you want to comment or apply for a license, you need to act by March 2, 2026.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
Exclusive License to Kyverna for Anti‑CD19 CARs
The National Cancer Institute is contemplating granting Kyverna Therapeutics an exclusive patent license (which may be worldwide) for developing, producing, and commercializing an anti‑CD19 CAR immunotherapy that uses either a non‑viral synthetic nanoparticle system or a viral system (excluding lentiviral) that encapsulates mRNA or DNA encoding a CAR with the Hu19 CDR sequences, for the treatment or prevention of B cell mediated autoimmune diseases.
Deadline to Comment or Apply for License
If you want to comment on or apply for this exclusive license, written comments and/or license applications must be received by the NCI Technology Transfer Center on or before March 2, 2026. License applications filed in response to this notice will be treated as objections to the grant and are presumed to contain business confidential information.
Field of Use Carve-Outs and Royalty Requirement
The contemplated exclusive license would exclude anti‑CD19 CAR approaches that use CRISPR/Cas9‑edited allogeneic T lymphocytes and autologous T lymphocytes engineered by lentivirus, and it does not include CAR constructs that exclusively use the FMC63 antigen binding domain. The prospective exclusive license will be royalty bearing.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20151, Notice of NIH Tribal Consultations and Listening Session
The NIH is inviting Tribal leaders and members to join two important meetings and a listening session during the National Congress of American Indians Annual Convention in October 2026. They’ll talk about new health research projects, renewing support for Tribal health centers, and shaping a new Tribal Data Sovereignty Policy. Tribes can also send their thoughts by November 20, 2026, helping shape future health programs and policies.
2026-19718, Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding two closed virtual meetings in October 2026 to review important grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists and research teams applying for grants should note these dates as they impact funding decisions but don’t involve public attendance.
2026-19804, Submission for OMB Review; 30-Day Comment Request; Generic Clearance for NIH Citizen Science and Crowdsourcing Projects (Office of the Director)
The NIH is asking for approval to keep collecting info from citizen science and crowdsourcing projects, making it easier to gather public input on health research. This affects anyone involved in these projects and invites comments by October 28, 2026. No new costs or big changes, just a smooth way to keep the data flowing for better science!
2026-19719, Center for Scientific Review; Amended Notice of Meeting
The NIH’s Center for Scientific Review is shortening a key meeting from two days to just one day on October 13, 2026, keeping the same 9 a.m. to 6 p.m. hours. This change affects members of the Surgical Sciences and Bioengineering review group and means less time in the room but no public access. No money changes or delays are expected—just a quicker, tighter meeting!
2026-19706, Draft NIH Policy on Sharing Summary Level Study Results With Clinical Research Participants
The NIH wants to make it easier for people who join clinical studies to get simple summaries of the study results. This new policy aims to boost trust and teamwork between researchers and participants, helping science move faster and better. They’re asking for your thoughts by October 26, 2026, so get ready to share your ideas!
2026-19431, Government-Owned Inventions; Availability for Licensing
The government is offering a new invention for licensing that makes stem cell transplants safer and less harsh, especially for leukemia patients and older folks. This tech uses a special protein to prepare patients for transplants without the tough side effects of chemo and radiation. Companies can start licensing this preclinical innovation now to help bring better treatments to market faster.
Previous / Next Documents
Previous: 2026-02906, Government Owned Inventions Available for License: Gait Assistance Systems and Methods of Control Thereof
The NIH is offering a license for a smart, robot-powered system that helps people with movement problems walk better by adapting to their unique way of moving. This invention uses machine learning to personalize support in real-time, making walking easier and more natural for kids and adults with conditions like cerebral palsy. Companies interested in bringing this tech to market should act soon to help improve lives and tap into a promising new market.
Next: 2026-02908, Bulk Manufacturer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to make large amounts of marijuana and related substances for clinical trials and customers. People who already make or use these drugs can comment or ask for a hearing by April 14, 2026. This move could speed up research and distribution, but no other drug activities are allowed under this registration.